Literature DB >> 1402626

Pulse cyclophosphamide therapy in Wegener's granulomatosis: a pilot study.

A A Drosos1, L I Sakkas, A Goussia, K C Siamopoulos, H M Moutsopoulos.   

Abstract

Five patients with Wegener's granulomatosis (WG) have been treated with 6- to 8-monthly pulses of intravenous cyclophosphamide (CP) and glucocorticoids in an open pilot study. One patient achieved complete remission sustained during 30 months of follow-up; one patient had features of active disease after 28 months of remission; two patients after an initial remission had an exacerbation of the disease and received continuous oral administration of CP, and one patient required continuous oral CP to control the symptoms. These results suggest that this regimen may not achieve a high degree of sustained remission in patients with WG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402626     DOI: 10.1111/j.1365-2796.1992.tb00584.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  5 in total

Review 1.  An unusual case of multiple cranial nerve palsies in Wegener's granulomatosis.

Authors:  A D Daderian; S Chayasirisobhon
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

Review 2.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

3.  Wegener granulomatosis causing sellar mass, hydrocephalus, and global pituitary failure.

Authors:  R D Bertken; V R Cooper
Journal:  West J Med       Date:  1997-07

Review 4.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  An uncommon presentation of Granulomatosis with Polyangiitis.

Authors:  Eleftherios Pelechas; Georgios Zouzos; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Mediterr J Rheumatol       Date:  2018-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.